|
1
|
Lorenzi M, Amonkar M, Zhang J, Mehta S and
Liaw KL: Epidemiology of microsatellite instability-high (MSI-H)
and deficient mismatch repair (dMMR) in solid tumors: A structured
literature review. J Oncol. 2020:18079292020. View Article : Google Scholar
|
|
2
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Okuma Y: Prospects for thymic carcinoma
treatment. Haigan. 64:821–827. 2024. View Article : Google Scholar
|
|
4
|
Koizumi T, Otsuki K, Tanaka Y, Noguchi T,
Fukushuima T, Kobayashi T, Takesumi O, Sekiguchi N and Hamanaka K:
National incidence and initial therapy for thymic carcinoma in
Japan: Based on analysis of hospital-based cancer registry data,
2009–2015. Jpn J Clin Oncol. 50:434–439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bakhos CT, Salami AC, Kaiser LR, Petrov RV
and Abbas AE: Thymic neuroendocrine tumors and thymic carcinoma:
Demographics, treatment, and survival. Innovations (Phila).
15:468–474. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirai F, Yamanaka T, Taguchi K, Daga H,
Ono A, Tanaka K, Kogure Y, Shimizu J, Kimura T, Fukuoka J, et al: A
multicenter phase II study of carboplatin and paclitaxel for
advanced thymic carcinoma: WJOG4207L. Ann Oncol. 26:363–368. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sato J, Satouchi M, Itoh S, Okuma Y, Niho
S, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, et al:
Lenvatinib in patients with advanced or metastatic thymic carcinoma
(REMORA): A multicentre, phase 2 trial. Lancer Oncol. 21:843–850.
2020. View Article : Google Scholar
|
|
8
|
Cho J, Kim HS, Ku BM, Choi YL, Cristescu
R, Han J, Sun JM, Lee SH, Ahn JS, Park K and Ahn MJ: Pembrolizumab
for patients with refractory or relapsed thymic epithelial Tumor:
An open-label phase II trial. J Clin Oncol. 37:2162–2170. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Giaccone G, Kim C, Thompson J, McGuire C,
Kallakury B, Chahine JJ, Maning M, Mogg R, Blumenschein WM, Tan MT,
et al: Pembrolizumab in patients with thymic carcinoma: A
single-arm, single-centre, phase 2 study. Lancet Oncol. 19:347–355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yokoyama S and Miyoshi T: Thymic tumors
and immune checkpoint inhibutors. J Thorac Dis. 10:S1509–S1515.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Akagi K, Oki E, Taniguchi H, Nakatani K,
Aoki D, Kuawata T and Yoahino T: Real-world data on microsatellite
instability status in various unresectable or metastatic solid
tumors. Cancer Sci. 112:1105–1113. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Repetto M, Conforti F, Pirola S, Calvello
M, Pala L, Bonanni B, Catania C, Curigliano G and De Pas T: Thymic
carcinoma with Lynch syndrome or microsatellite instability, a rare
entity responsive to immunotherapy. Eur J Cancer. 153:162–167.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Watanabe M, Tanakaya K, Furukawa S,
Shiotani T, Sato Y, Taniguchi F, Kanaya N, Aoki H, Sugano K, Ishida
H, et al: Two cases of thymic cancer in patients with Lynch
syndrome. Intern Med. 62:649–653. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yanagihara T, Kawamura T, Maki N,
Kobayashi N, Kikuchi S, Goto Y, Ichimura H and Sato Y: Practical
methods to differentiate thymic malignancies. Surg Today.
54:899–906. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Igai H, Matsuura N, Tarumi S, Chang SS,
Misaki N, Go T, Ishikawa S and Yokomise H: Usefulness of
[18F]fluoro-2-deoxy-D-glucose positron emission
tomography for predicting the World Health Organization malignancy
grade of thymic epithelial tumors. Eur J Cardiothorac Surg.
40:143–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM classification of malignant tumours. 8th edition.
Wiley-Blackwell; Oxford: pp. 114–124. 2017
|
|
17
|
Masaoka A, Monden Y, Nakahara K and
Tanioka T: Follow-up study of thymomas with special reference to
their clinical stages. Cancer. 48:2485–2492. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pharmaceuticals and Medical Devices
Agency, . KEYTRUDA® Intravenous Infusion 100 mg: Package
Insert. Version 25. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/14987185809730Accessed
(In Japanese). September 20–2025
|
|
19
|
Pharmaceutical Evaluation Division,
Pharmaceutical Safety, Environmental Health and Bureau, Ministry of
Health and Labour Welfare, . Report on the Deliberation Results:
Keytruda (pembrolizumab). https://www.pmda.go.jp/files/000231921.pdfMarch
8–2025
|
|
20
|
Hellmann MD, Nathanson T, Rizvi H, Creelan
BC, Sanchez-Vega F, Ahuja A, Ni A, Novik JB, Mangarin LMB,
Abu-Akeel M, et al: Genomic features of response to combination
immunotherapy in patients with advanced non-small-cell lung cancer.
Cancer Cell. 33:843–852.e4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vanderwalde A, Spetzler D, Xiao N,
Gatalica Z and Marshall J: Microsatellite instability status
determined by next-generation sequencing and compared with PD-L1
and tumor mutational burden in 11,348 patients. Cancer Med.
7:746–756. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Umar A, Boland CR, Terdiman JP, Syngal S,
de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ,
Hamelin R, et al: Revised Bethesda Guidelines for hereditary
nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite
instability. J Natl Cancer Inst. 96:261–268. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vasen HF, Watson P, Mecklin JP and Lynch
HT: New clinical criteria for hereditary nonpolyposis colorectal
cancer (HNPCC, Lynch syndrome) proposed by the international
collaborative group on HNPCC. Gastroenterology. 116:1453–1456.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaneko T, Sekine A, Komatsu S, Otoshi R,
Haga S, Tagami Y, Kaneko T and Ogura T: Successful pembrolizumab
treatment for microsatellite instability-high thymoma: A case
report. Respir Investig. 62:517–519. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Camargo Correia GC, Tawfiq R, Lou Y,
Zhao Y, Li S, Ernani V, Parikh K and Manochakian R: Immune
checkpoint inhibitors (ICI) in thymic epithelial tumors (TET): A
real world assessment of efficacy and toxicity. J Clin Oncol. 43
(Suppl 16):e201412025.
|
